These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34861268)

  • 1. Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
    Hong CR; Buckley CD; Wong WW; Anekal PV; Dickson BD; Bogle G; Hicks KO; Hay MP; Wilson WR
    Radiother Oncol; 2022 Jan; 166():162-170. PubMed ID: 34861268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
    Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib.
    Mentzel J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
    Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR
    Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
    Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
    Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
    Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
    Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
    Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
    Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
    Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense inhibition of ATM gene enhances the radiosensitivity of head and neck squamous cell carcinoma in mice.
    Zou J; Qiao X; Ye H; Yang Y; Zheng X; Zhao H; Liu S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):56. PubMed ID: 18950535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
    Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
    J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues.
    Baker JHE; Kyle AH; Liu NA; Wang T; Liu X; Teymori S; Banáth JP; Minchinton AI
    Mol Cancer Ther; 2024 Sep; 23(9):1230-1240. PubMed ID: 38781104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinnarizine and flunarizine as radiation sensitisers in two murine tumours.
    Wood PJ; Hirst DG
    Br J Cancer; 1988 Dec; 58(6):742-5. PubMed ID: 3224079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
    Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
    Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.
    Dehghankelishadi P; Badiee P; Maritz MF; Dmochowska N; Thierry B
    J Nanobiotechnology; 2023 Mar; 21(1):102. PubMed ID: 36945003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.
    Horsman MR; Siemann DW; Chaplin DJ; Overgaard J
    Radiother Oncol; 1997 Nov; 45(2):167-74. PubMed ID: 9424008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
    Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
    Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
    Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
    Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD7648, a DNA-PKcs inhibitor, overcomes radioresistance in Hep3B xenografts and cells under tumor hypoxia.
    Ha J; Park M; Lee Y; Choi SH; Kim BS; Ha H; Jeong YK
    Am J Cancer Res; 2023; 13(10):4918-4930. PubMed ID: 37970336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
    Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.